部分多巴胺D2受体激动剂阿立哌唑与青少年神经性厌食症患者体重增加有关。
The partial dopamine D2 receptor agonist aripiprazole is associated with weight gain in adolescent anorexia nervosa.
作者信息
Frank Guido K W, Shott Megan E, Hagman Jennifer O, Schiel Marissa A, DeGuzman Marisa C, Rossi Brogan
机构信息
Department of Psychiatry, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
Department of Neuroscience, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
出版信息
Int J Eat Disord. 2017 Apr;50(4):447-450. doi: 10.1002/eat.22704. Epub 2017 Mar 23.
Abstract
OBJECTIVE
Finding medication to support treatment of anorexia nervosa has been difficult. Neuroscience-based approaches may help in this effort. Recent brain imaging studies in adults and adolescents with anorexia nervosa suggest that dopamine-related reward circuits are hypersensitive and could provide a treatment target.
METHODS
Here, we present a retrospective chart review of 106 adolescents with anorexia nervosa some of whom were treated with the dopamine D2 receptor partial agonist aripiprazole during treatment in a specialized eating disorder program.
RESULTS
The results show that aripiprazole treatment was associated with greater increase in body mass index (BMI) during treatment.
DISCUSSION
The use of dopamine receptor agonists may support treatment success in anorexia nervosa and should be further investigated.
摘要
目的
寻找支持神经性厌食症治疗的药物一直颇具难度。基于神经科学的方法或许有助于此。近期针对患有神经性厌食症的成人和青少年的脑成像研究表明，与多巴胺相关的奖赏回路高度敏感，可能提供一个治疗靶点。
方法
在此，我们对106名患有神经性厌食症的青少年进行了一项回顾性病历审查，其中部分青少年在一个专门的饮食失调项目治疗期间接受了多巴胺D2受体部分激动剂阿立哌唑的治疗。
结果
结果显示，在治疗期间，阿立哌唑治疗与体重指数（BMI）的更大增幅相关。
讨论
多巴胺受体激动剂的使用可能有助于神经性厌食症治疗取得成功，应进一步开展研究。
相似文献
1
The partial dopamine D2 receptor agonist aripiprazole is associated with weight gain in adolescent anorexia nervosa.部分多巴胺D2受体激动剂阿立哌唑与青少年神经性厌食症患者体重增加有关。
Int J Eat Disord. 2017 Apr;50(4):447-450. doi: 10.1002/eat.22704. Epub 2017 Mar 23.
2
Association of Elevated Reward Prediction Error Response With Weight Gain in Adolescent Anorexia Nervosa.青少年神经性厌食症中奖励预测误差反应升高与体重增加的关联。
Am J Psychiatry. 2017 Jun 1;174(6):557-565. doi: 10.1176/appi.ajp.2016.16060671. Epub 2017 Feb 24.
3
Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial.初治及非初治精神分裂症患者中多巴胺D2受体拮抗剂和部分激动剂的随机对照试验
Eur Arch Psychiatry Clin Neurosci. 2015 Oct;265(7):579-88. doi: 10.1007/s00406-015-0605-1. Epub 2015 May 28.
4
Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic.阿立哌唑：一种部分多巴胺D2受体激动剂抗精神病药物。
Expert Opin Investig Drugs. 2003 Apr;12(4):655-62. doi: 10.1517/13543784.12.4.655.
5
D-Cycloserine facilitation of exposure therapy improves weight regain in patients with anorexia nervosa: a pilot randomized controlled trial.D-环丝氨酸辅助暴露疗法可改善神经性厌食症患者的体重反弹：一项初步随机对照试验。
J Clin Psychiatry. 2015 Jun;76(6):e787-93. doi: 10.4088/JCP.14m09299.
6
[Aripiprazole as dopamine partial agonist model: Basic concepts and clinical impact].[阿立哌唑作为多巴胺部分激动剂模型：基本概念与临床影响]
Encephale. 2018 Dec;44(6):558-564. doi: 10.1016/j.encep.2018.10.003. Epub 2018 Nov 20.
7
Aripiprazole acts as a selective dopamine D2 receptor partial agonist.阿立哌唑作为一种选择性多巴胺D2受体部分激动剂。
Expert Opin Investig Drugs. 2007 Jun;16(6):771-5. doi: 10.1517/13543784.16.6.771.
8
Association of Brain Reward Learning Response With Harm Avoidance, Weight Gain, and Hypothalamic Effective Connectivity in Adolescent Anorexia Nervosa.青少年神经性厌食症中大脑奖励学习反应与回避伤害、体重增加和下丘脑有效连接的关联。
JAMA Psychiatry. 2018 Oct 1;75(10):1071-1080. doi: 10.1001/jamapsychiatry.2018.2151.
9
Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors.阿立哌唑是一种新型抗精神病药物，对人多巴胺D2受体具有高亲和力的部分激动剂。
J Pharmacol Exp Ther. 2002 Jul;302(1):381-9. doi: 10.1124/jpet.102.033175.
10
Weight gained during treatment predicts 6-month body mass index in a large sample of patients with anorexia nervosa using ensemble machine learning.使用集成机器学习方法，治疗期间体重增加可预测大量神经性厌食症患者 6 个月时的体重指数。
Int J Eat Disord. 2024 Aug;57(8):1653-1667. doi: 10.1002/eat.24208. Epub 2024 Apr 12.
引用本文的文献
1
Mirtazapine Is Associated With Shorter Hospital Stay in Pediatric Avoidant Restrictive Food Intake Disorder-A Retrospective Chart Review.米氮平与儿童回避性限制性食物摄入障碍患者住院时间缩短相关——一项回顾性病历审查
Int J Eat Disord. 2025 Jul;58(7):1345-1351. doi: 10.1002/eat.24449. Epub 2025 Apr 23.
2
Use of atypical antipsychotics in individuals with anorexia nervosa.非典型抗精神病药物在神经性厌食症患者中的应用。
Ment Health Clin. 2025 Feb 3;15(1):1-8. doi: 10.9740/mhc.2025.02.001. eCollection 2025 Feb.
3
Olanzapine for young PEople with aNorexia nervosa (OPEN): results of a feasibility study.奥氮平治疗神经性厌食症青年患者（OPEN）：一项可行性研究结果。
BMC Psychiatry. 2024 Nov 7;24(1):779. doi: 10.1186/s12888-024-06215-y.
4
Psychopharmacology Review for Eating Disorders Among Children, Adolescents, and Adults.儿童、青少年和成人饮食失调的精神药理学综述
Focus (Am Psychiatr Publ). 2024 Jul;22(3):307-311. doi: 10.1176/appi.focus.20230043. Epub 2024 Jun 28.
5
Wernicke Encephalopathy Caused by Avoidance-Restrictive Food Intake Disorder in a Child: A Case-Based Review.儿童回避性限制性摄食障碍所致韦尼克脑病：病例回顾
Diseases. 2024 May 24;12(6):112. doi: 10.3390/diseases12060112.
6
Pharmacological Studies in Eating Disorders: A Historical Review.进食障碍的药理学研究：历史回顾。
Nutrients. 2024 Feb 22;16(5):594. doi: 10.3390/nu16050594.
7
Atypical antipsychotic use does not impact weight gain for individuals with extreme anorexia nervosa: a retrospective case-control study.非典型抗精神病药物的使用对患有极端神经性厌食症的个体的体重增加没有影响：一项回顾性病例对照研究。
J Eat Disord. 2023 Dec 6;11(1):215. doi: 10.1186/s40337-023-00941-6.
8
Antipsychotic effects on anthropometric outcomes in anorexia nervosa: a retrospective chart review of hospitalized children and adolescents.抗精神病药物对神经性厌食症人体测量结果的影响：对住院儿童和青少年的回顾性病历审查
J Eat Disord. 2023 Sep 6;11(1):151. doi: 10.1186/s40337-023-00862-4.
9
Pharmacotherapy, alternative and adjunctive therapies for eating disorders: findings from a rapid review.饮食失调的药物治疗、替代疗法和辅助疗法：快速综述的结果
J Eat Disord. 2023 Jul 6;11(1):112. doi: 10.1186/s40337-023-00833-9.
10
Efficacy and tolerance of second-generation antipsychotics in anorexia nervosa: A systematic scoping review.第二代抗精神病药治疗神经性厌食症的疗效和耐受性：系统范围综述。
PLoS One. 2023 Mar 16;18(3):e0278189. doi: 10.1371/journal.pone.0278189. eCollection 2023.
本文引用的文献
1
Association of Elevated Reward Prediction Error Response With Weight Gain in Adolescent Anorexia Nervosa.青少年神经性厌食症中奖励预测误差反应升高与体重增加的关联。
Am J Psychiatry. 2017 Jun 1;174(6):557-565. doi: 10.1176/appi.ajp.2016.16060671. Epub 2017 Feb 24.
2
The Role of Psychotropic Medications in the Management of Anorexia Nervosa: Rationale, Evidence and Future Prospects.精神药物在神经性厌食症治疗中的作用：理论依据、证据及未来前景
CNS Drugs. 2016 May;30(5):419-42. doi: 10.1007/s40263-016-0335-6.
3
The Perfect Storm - A Bio-Psycho-Social Risk Model for Developing and Maintaining Eating Disorders.《完美风暴——一种用于发展和维持饮食失调的生物-心理-社会风险模型》
Front Behav Neurosci. 2016 Mar 10;10:44. doi: 10.3389/fnbeh.2016.00044. eCollection 2016.
4
Melanocortin 4 Receptor and Dopamine D2 Receptor Expression in Brain Areas Involved in Food Intake.参与摄食的脑区中黑素皮质素 4 受体和多巴胺 D2 受体的表达。
Endocrinol Metab (Seoul). 2015 Dec;30(4):576-83. doi: 10.3803/EnM.2015.30.4.576.
5
Aripiprazole, a partial dopamine agonist to improve adolescent anorexia nervosa-A case series.阿立哌唑，一种用于改善青少年神经性厌食症的部分多巴胺激动剂——病例系列
Int J Eat Disord. 2016 May;49(5):529-533. doi: 10.1002/eat.22485. Epub 2015 Nov 23.
6
Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism.阿立哌唑作用机制的最新进展：对超越多巴胺受体拮抗作用的抗精神病策略的转化性见解。
CNS Drugs. 2015 Sep;29(9):773-99. doi: 10.1007/s40263-015-0278-3.
7
Could dopamine agonists aid in drug development for anorexia nervosa?多巴胺激动剂能否有助于神经性厌食症的药物研发？
Front Nutr. 2014 Nov 3;1:19. doi: 10.3389/fnut.2014.00019. eCollection 2014.
8
Atypical antipsychotics as augmentation therapy in anorexia nervosa.非典型抗精神病药物作为神经性厌食症的增效治疗手段。
PLoS One. 2015 Apr 29;10(4):e0125569. doi: 10.1371/journal.pone.0125569. eCollection 2015.
9
Selective disruption of dopamine D2 receptors in pituitary lactotropes increases body weight and adiposity in female mice.选择性破坏催乳素细胞中的多巴胺 D2 受体可增加雌性小鼠的体重和肥胖度。
Endocrinology. 2014 Mar;155(3):829-39. doi: 10.1210/en.2013-1707. Epub 2013 Jan 1.
10
Effects of repeated treatment with the dopamine D2/D3 receptor partial agonist aripiprazole on striatal D2/D3 receptor availability in monkeys.多巴胺D2/D3受体部分激动剂阿立哌唑重复治疗对猴子纹状体D2/D3受体可利用性的影响。
Psychopharmacology (Berl). 2013 Sep 29. doi: 10.1007/s00213-013-3274-7.
Zotero 插件